Expert consensus on the multifaceted utility of alginates in addressing diverse manifestations of acid reflux
DOI:
https://doi.org/10.18203/2349-3933.ijam20243441Keywords:
Alginates, GERD, Regurgitation, Nocturnal GERD, Refractory GERD, IndiaAbstract
Gastroesophageal reflux disease (GERD) is one of the most frequent reasons for seeking outpatient gastroenterology consultations. Current professional guidelines advocate the use of proton pump inhibitors (PPIs) as the primary medical approach to manage GERD. However, PPIs may not be as effective, especially for certain patients like those with non-erosive reflux disease (NERD). An alternative strategy for addressing symptomatic GERD involves obstructing the flow of acidic refluxate. Alginate-based pharmaceutical formulations have proven effective in alleviating symptoms of acid reflux for many years and provide rapid relief of symptoms with a long duration of action. Alginic acid derivatives, or alginates, combat acid reflux through a unique mechanism: they create a physical barrier that displaces the post-prandial acid pocket. Alginates have recently garnered renewed interest for promoting symptomatic relief especially when employed alongside antacids or PPIs. Here, the role of alginates is reviewed in the treatment of various profiles of acid reflux, including post-prandial acid reflux, nocturnal GERD, refractory GERD, and GERD during pregnancy, along with the opinion of expert gastroenterologists on the same. The experts believed that not all alginate formulations are equivalent and raft strength is the most important physicochemical property to be considered while selecting the alginate-based product. The physicochemical properties of the rafts eventually impact their effectiveness in relieving symptoms in clinical settings.
Metrics
References
Antunes C, Aleem A, Curtis SA. Gastroesophageal Reflux Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2023.
Rai S, Kulkarni A, Ghoshal UC. Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: A meta-analysis and meta-regression study. Indian J Gastroenterol. 2021;40(2):209-19.
Chatila AT, Nguyen MTT, Krill T, Roark R, Bilal M, Reep G. Natural history, pathophysiology and evaluation of gastroesophageal reflux disease. Dis Mon. 2020;66(1):100848.
Bhatia SJ, Makharia GK, Abraham P, Bhat N, Kumar A, Reddy DN, et al. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol. 2019;38(5):411-40.
Clarrett DM, Hachem C. Gastroesophageal Reflux Disease (GERD). Mo Med. 2018;115(3):214-8.
Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27-56.
Goh KL, Lee YY, Leelakusolvong S, Makmun D, Maneerattanaporn M, Quach DT, et al. Consensus statements and recommendations on the management of mild-to-moderate gastroesophageal reflux disease in the Southeast Asian region. JGH Open Access J Gastroenterol Hepatol. 2021;5(8):855-63.
Bor S, Kalkan İH, Çelebi A, Dinçer D, Akyüz F, Dettmar P, et al. Alginates: From the ocean to gastroesophageal reflux disease treatment. Turk J Gastroenterol Off J Turk Soc Gastroenterol. 2019;30(2):109-36.
Savarino V, Marabotto E, Zentilin P, Demarzo MG, de Bortoli N, Savarino E. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. Drug Des Devel Ther. 2021;15:1609-21.
Kroch DA, Madanick RD. Medical Treatment of Gastroesophageal Reflux Disease. World J Surg. 2017;41(7):1678-84.
Ahmed A, Clarke JO. Proton Pump Inhibitors (PPI). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
Leiman DA, Riff BP, Morgan S, Metz DC, Falk GW, French B, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30(5):1-9.
Nugent CC, Falkson SR, Terrell JM. H2 Blockers. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
Savla HM, Naik IV, Gargote C, Shashidhar N, Nair S, Menon MD. Physicochemical properties of various alginate-based raft-forming antacid products: a comparative study. Int J Basic Clin Pharmacol. 2021;10(12):1.
Hershcovici T, Fass R. Pharmacological management of GERD: where does it stand now? Trends Pharmacol Sci. 2011;32(4):258-64.
Pouchain D, Bigard MA, Liard F, Childs M, Decaudin A, McVey D. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol. 2012;12:18.
Wilkinson J, Wade A, Thomas SJ, Jenner B, Hodgkinson V, Coyle C. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2019;31(1):86.
Reimer C, Lødrup AB, Smith G, Wilkinson J, Bytzer P. Randomised clinical trial:alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016;43(8):899-909.
Maestri L. Treatment with sodium alginate of gastroesophageal reflux disease in childhood: efficacy and tolerance assessment. Pediatr Medica E Chir Med Surg Pediatr. 2001;23(3-4):187-9.
Strugala V, Bassin J, Swales VS, Lindow SW, Dettmar PW, Thomas ECM. Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy. ISRN Obstet Gynecol. 2012;2012:481870.
Kahrilas PJ, McColl K, Fox M, O'rourke L, Sifrim D, Smout AJ, et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol. 2013;108(7):1058-64.
De Giorgi F, Palmiero M, Esposito I, Mosca F, Cuomo R. Pathophysiology of gastro- oesophageal reflux disease. Acta Otorhinolaryngol Ital. 2006;26(5):241-6.
Waleleng BJ, Simadibrata M, Syam AF. The pathophysiology of gastroesophageal reflux disease. Indones J Gastroenterol, Hepatol Dig Endosc. 2007;8(3):84-90.
Mandel D, Brodie J. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000;14(6):669-90.
Rohof WO, Bennink RJ, Smout AJPM, Thomas E, Boeckxstaens GE. An Alginate-Antacid Formulation Localizes to the Acid Pocket to Reduce Acid Reflux in Patients with Gastroesophageal Reflux Disease. Clin Gastroenterol Hepatol. 2013;11(12):1585-91.
Kwiatek MA, Roman S, Fareeduddin A, Pandolfino JE, Kahrilas PJ. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial “acid pocket” in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34(1):59-66.
Gaddam S, Maddur H, Wani S, Gupta N, Singh M, Singh V, et al. Risk Factors for Nocturnal Reflux in a Large GERD Cohort. J Clin Gastroenterol. 2011;45(9):764-8.
Orr WC. Management of nighttime gastroesophageal reflux disease. Gastroenterol Hepatol. 2007;3(8):605-6.
Lee KJ. Nocturnal gastroesophageal reflux: assessment and clinical implications. J Neurogastroenterol Motil. 2011;17(2):105-7.
Fornari F, Blondeau K, Mertens V, Tack J, Sifrim D. Nocturnal Gastroesophageal Reflux Revisited by Impedance-pH Monitoring. J Neurogastroenterol Motil. 2011;17(2):148-57.
Ates F, Vaezi MF. Insight Into the Relationship Between Gastroesophageal Reflux Disease and Asthma. Gastroenterol Hepatol. 2014;10(11):729-36.
Tutuian R, Castell DO. Nocturnal acid breakthrough-approach to management. Med Gen Med. 2004;6(4):11.
Naik RD, Meyers MH, Vaezi MF. Treatment of Refractory Gastroesophageal Reflux Disease. Gastroenterol Hepatol. 2020;16(4):196-205.
Shibli F, Skeans J, Yamasaki T, Fass R. Nocturnal Gastroesophageal Reflux Disease (GERD) and Sleep: An Important Relationship That Is Commonly Overlooked. J Clin Gastroenterol. 2020;54(8):663-74.
Giannini EG, Zentilin P, Dulbecco P, Iiritano E, Bilardi C, Savarino E, et al. A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. Dig Dis Sci. 2006;51(11):1904-9.
Chatfield S. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease. Curr Med Res Opin. 1999;15(3):152-9.
Chiu CT, Hsu CM, Wang CC, Chang JJ, Sung CM, Lin CJ, et al. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther. 2013;38(9):1054-64.
Manabe N, Haruma K, Ito M, Takahashi N, Takasugi H, Wada Y, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial: Efficacy of adding sodium alginate. Dis Esophagus. 2012;25(5):373-80.
Ang D, How CH, Ang TL. Persistent gastro-oesophageal reflux symptoms despite proton pump inhibitor therapy. Singapore Med J. 2016;57(10):546-51.
Mermelstein J, Chait Mermelstein A, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol. 2018;11:119-34.
Yadlapati R, DeLay K. PPI Refractory Gastroesophageal Reflux Disease. Med Clin North Am. 2019;103(1):15-27.
Rettura F, Bronzini F, Campigotto M, Lambiase C, Pancetti A, Berti G, et al. Refractory Gastroesophageal Reflux Disease: A Management Update. Front Med. 2021;8:765061.
El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32(6):720-37.
Bor S, Kalkan İH. Medical treatment of gastroesophageal reflux disease. Turk J Gastroenterol Off J Turk Soc Gastroenterol. 2017;28(1):S48-52.
Hunt R, Armstrong D, Katelaris P, Afihene M, Bane A, Bhatia S, et al. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol. 2017;51(6):467-78.
Lai IR, Wu MS, Lin JT. Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy-negative reflux disease. World J Gastroenterol. 2006;12(5):747-54.
Vărșa RG, Ciobanu AM, “Filantropia” Clinical Hospital, Bucharest, Romania, “Carol Davila” University of Medicine and Farmacy, Bucharest, Romania, Cimpoca-Raptis BA, et al. Gastroesophageal reflux disease in pregnancy. Romanian J Med Pract. 2021;16(S3):28-31.
Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005;22(9):749-57.
Dagli U, Kalkan IH, Clinic of Gastroenterology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey. Treatment of reflux disease during pregnancy and lactation. Turk J Gastroenterol. 2020;28(1):S53-6.
Ali RAR, Hassan J, Egan LJ. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. BMC Gastroenterol. 2022;22(1):219.